Perceval™ Plus

• sutureless and self-expanding
• superlastic stent that self-expands in place (no need to knot the sutures) for optimal valve sealing
• fully atraumatic collapsing that prevents any possible tissue damage 

• long durability
• suitable for minimally invasive procedures
• shortens duration of procedure significantly  

• Clear visibility: The Nitinol stent ensures maximum precision under fluoroscopy and CT scan to identify landmarks that facilitate the ViV procedure.
• Even circumferential expansion: The inflow ring can be expanded up to 2.5 mm above its nominal size. This allows for hemodynamic advantages and greater compatibility with TAVI models and sizes.

• Minimized risk of coronary obstruction: Leaflets remain open when a TAVI is deployed inside. The sinusoidal struts and the open leaflets create a space between the coronary ostia and the leaflets themselves, which is preserved even after TAVI deployment.
• Minimized risk of sinus sequestration: While open, leaflets do not touch the STJ and thereby avoid sinus sequestration. 

The innovative FREE Tissue Treatment in Perceval™ Plus addresses both major causes of valve calcification: phospholipids and aldehydes.  

An aldehyde-free storage solution ensures negligible toxicity for the patient and a faster procedure for the surgeon, since no rinsing is required. 

• new phospholipids removal
• glutaraldehyde fixation and sterilization
• enhanced aldehyde neutralization
• aldehyde-free storage solution
• ready-to-use
• designed to improve durability 

Cost-consequence analysis 2022

“The use of the Perceval S valve is clinically safe and effective. A shorter procedural time in the sutureless group is associated with better clinical outcomes and reduced hospital costs.” 

Panagiotopoulos et al. Kardiochir Torakochirurgia 2022. DOI: 10.5114/kitp.2022.114551  

Clinical study 2022

“These data represent the longest follow-up available for the Perceval sutureless valve. We observed favorable early outcomes, low rates of early mortality, stroke and other major complications. Valve durability is promising with low rates of valve degeneration and a limited need for reintervention.”

Lamberigts et al. J Thorac Cardiovasc Surg 2022. DOI: 10.1016/j. Jtcvs.2022.09.053 

Clinical study 2021

“After more than 11 years of continued clinical use of the Perceval sutureless valve, we observe low mortality and stroke rates, with good hemodynamic behavior of the valve. None of our patients was reoperated for structural valve degeneration. Because of the key benefits of this rapid-deployment valve, it has an added value in surgical aortic valve replacement.” 

Szecel et al. Ann Thorac Surg 2021. DOI: 10.1016/j.athoracsur.2020.06.064  

International registry 2020

“In this large prospective international registry, MI-AVR [minimally invasive aortic valve replacement] with Perceval valve confirmed to be safe, reproducible, and effective in an intermediate-risk population, providing excellent clinical recovery both in early and mid-term follow-up.” 

Glauber et al. Innovations (Phila) 2020. DOI: 10.1177/1556984519892585